Most claims about AOD 9604 benefits trace back to one idea: that a small fragment of human growth hormone can strip fat without the side effects of the full hormone. That is a real research story, but the honest version is narrower than the sales copy. AOD-9604 showed clear fat-burning activity in animals, a clean safety record in people, and then failed its largest human weight-loss trial.
The Compound Universe Take: AOD-9604 (also called hGH fragment 176-191) is a synthetic peptide studied mainly for fat loss. In animals it triggers lipolysis and fat oxidation, and in humans it appears safe and does not raise IGF-1. But its biggest human obesity trial did not beat placebo, so it is best described as research-stage, not a proven weight-loss therapy.
New here? Start with the peptides studied for fat loss overview for the full category, then use this page for the specific compound.
What AOD-9604 is
AOD-9604 is a 16-amino-acid peptide built from the C-terminal region of human growth hormone (residues 176-191), with a tyrosine added at one end to stabilize it [1][2]. The “AOD” stands for anti-obesity drug, the label its original developer, Metabolic Pharmaceuticals, used during clinical development.
The design goal was specific. AOD-9604 copies the fat-metabolizing tail of growth hormone while leaving out the parts that drive growth signaling [1]. In practice that means researchers wanted the lipolytic effect without the blood-sugar and IGF-1 changes that full-length hGH produces.
| Attribute | Detail |
|---|---|
| Class | Synthetic hGH fragment (176-191), 16 amino acids |
| Primarily studied for | Fat loss / lipolysis; explored for cartilage support |
| Evidence tier | Animal (strong) + Human safety; efficacy trial negative |
| Legal status (US) | Not FDA-approved as a drug; sold research-use-only; WADA-prohibited in sport |
How AOD-9604 is proposed to work
The mechanism people cite for AOD 9604 benefits centers on the fat cell, not the growth-hormone receptor.
In obese mice, AOD-9604 increased fat oxidation and reduced weight gain during chronic treatment (Animal) [1]. Follow-up work using beta-3 adrenergic receptor knockout mice suggested the compound acts partly through beta-3 adrenergic signaling, the same pathway involved in stimulated fat breakdown (Animal) [1][2].
Two things separate it from growth hormone itself. AOD-9604 did not stimulate IGF-1 production in human testing, and it did not worsen carbohydrate metabolism the way hGH can (Human) [3]. That combination is the core of the peptide’s appeal: fat-cell activity without the systemic hormone load.
The honest limit sits right here. The cell-level story is largely animal and mechanistic. It explains why the compound was interesting, not that it reliably reduces body fat in people.
What the human research actually found
This is where the marketing and the data separate.
Early human work looked promising. A 12-week study reported that oral AOD-9604 produced modestly more weight loss than placebo in obese adults, on the order of about 2 kg, with a favorable safety profile (Human pilot) [2]. That result drove much of the optimism that still circulates today.
The larger, longer trial did not confirm it. AOD-9604 failed to reach statistical significance versus placebo in its pivotal 24-week obesity trial, and Metabolic Pharmaceuticals ended the obesity drug program in 2007 (Human) [2]. Across roughly six trials and hundreds of participants, the peptide was consistently safe but not consistently effective for weight loss.
So the strongest evidence-backed statement is a split one: safety data are reassuring, efficacy data for fat loss in humans are not.
Read this before the hype: AOD-9604 is not an FDA-approved drug for weight loss or any other condition. This page summarizes published research; it is not medical advice, a dosing guide, or an endorsement of use. It reports what studies found, never what to take.
Legal and research-use status
AOD-9604 sits in an unusual regulatory position that fuels a lot of confusion.
As a drug, it is not FDA-approved, and its formal obesity development was discontinued (Regulatory) [2]. Separately, an independent expert panel concluded AOD-9604 was Generally Recognized As Safe (GRAS) for use in foods at the intended levels, a nutraceutical pathway distinct from drug approval (Regulatory) [3].
In sport, the picture is stricter. AOD-9604 is prohibited by the World Anti-Doping Agency and is tested for in competition, so athletes should treat it as a banned substance [2].
Most material sold online is labeled “for research use only,” which is not the same as approved for human use. Legal status varies by jurisdiction and continues to change.
| Question | What the research says | Evidence tier |
|---|---|---|
| Does it burn fat? | Yes in obese mice; increased fat oxidation and lipolysis | Animal |
| Does it work in people? | Small pilot positive; pivotal 24-week trial negative | Human |
| Does it raise IGF-1? | No measurable IGF-1 increase in human testing | Human |
| Is it safe? | Well tolerated; GRAS panel cleared it for food use | Human / Regulatory |
| Is it legal? | Not FDA-approved as a drug; WADA-banned in sport | Regulatory |
Key takeaways
- AOD-9604 is a growth hormone fragment (residues 176-191) engineered to keep hGH lipolytic activity while dropping its growth signaling [1].
- Its fat-loss mechanism is best documented in mice, where it raised fat oxidation partly through beta-3 adrenergic receptor activity [1][2].
- The peptide does not raise IGF-1 in human testing, which separates it from full-length growth hormone [3].
- Its largest human obesity trial did not beat placebo, and the obesity drug program was halted in 2007 [2].
- Across the record, AOD-9604 reads as safe but unproven for weight loss, and it remains WADA-prohibited in sport.
Frequently asked questions
What are the main AOD-9604 benefits studied so far?
The most studied benefit is fat loss through increased lipolysis and fat oxidation, shown mainly in obese mice. In humans the compound looks safe and does not raise IGF-1, but a large trial did not confirm meaningful weight loss.
Is AOD-9604 the same as HGH fragment 176-191?
Essentially yes. AOD-9604 is a modified version of the 176-191 fragment of human growth hormone, with a tyrosine added at one end for stability.
Does AOD-9604 actually cause weight loss in people?
A small 12-week study reported modest extra weight loss versus placebo, but the pivotal 24-week trial did not reach statistical significance. Human efficacy for fat loss is therefore not established.
Is AOD-9604 FDA-approved?
No. It is not FDA-approved as a drug. An expert panel separately rated it Generally Recognized As Safe for food use, which is a different pathway from drug approval.
Does AOD-9604 raise IGF-1 like growth hormone?
No measurable IGF-1 increase was seen in human testing. That is one of the features that distinguishes it from full-length human growth hormone.
Is AOD-9604 banned in sports?
Yes. AOD-9604 is on the World Anti-Doping Agency prohibited list and is tested for in competition, so athletes should treat it as banned.
Interest in AOD-9604 sits where growth-hormone biology meets fat metabolism, since the peptide is a C-terminal fragment of human growth hormone (residues 176-191) that appears to drive lipolysis and fat oxidation through beta-3 adrenergic receptor signaling without stimulating IGF-1 or disturbing glucose control; Compound Universe tracks this hexadecapeptide alongside related fat-loss research compounds and regulatory records so the summary reflects trial outcomes and GRAS and WADA status rather than marketing claims.
The bottom line on AOD 9604 benefits is a two-part answer worth repeating: the fat-metabolism mechanism is real and well documented in animals, and the human safety record is clean, but the peptide never proved it could reliably reduce body fat in people, which is why it remains a research compound rather than an approved therapy.
Compare next: AOD-9604 vs HGH fragment 176-191 | another fat-loss research peptide | are peptides legal?
References
- Heffernan MA, Thorburn AW, Fam B, Summers R, Conway-Campbell B, Waters MJ, Ng FM. Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment. Int J Obes Relat Metab Disord. 2001. PMID 11673763.
- Valentino MA, Lin JE, Waldman SA. Central and Peripheral Molecular Targets for Antiobesity Pharmacotherapy. Clin Pharmacol Ther. 2010;87(6):652-662. doi:10.1038/clpt.2010.57. PMID 20445536.
- Stier H, Vos E, Kenley D. Safety and Tolerability of the Hexadecapeptide AOD9604 in Humans. J Endocrinol Metab. 2013;3(1-2):7-15. doi:10.4021/jem157w.